Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and more than $650 million in milestones. | Eli Lilly is beefing up muscle health ...

Eli Lilly (NYSE:LLY) announced a significant global licensing and research collaboration with Juvena Therapeutics to explore ...

The Department of Health and Human Services is allegedly denying clinical trial funding for biotechs based on their ties to ...

Research will leverage world’s first AI-enabled screening platform for mapping the therapeutic potential of secreted signaling proteins, developed by JuvenaCollaboration aims to accelerate the ...

California-based clinical-stage biotech Juvena Therapeutics has entered a global licensing and multi-target research ...

The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for beginners now. On June 11, Eli Lilly announced a ...

A clinical-stage biotech company based in Redwood City, California, developing tissue-restorative biologics for chronic ...

Juvena Therapeutics works with a type of protein from the body that can spark regenerative effects. Now the startup has $41 million to advance its pipeline, including a lead program in development ...

Biotechnology startup Juvena Therapeutics Inc. has raised $41 million in new venture-capital funding to advance technology that could expand the range of treatments for chronic conditions and ...

REDWOOD CITY, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Juvena Therapeutics, Inc. (“Juvena”), a clinical-stage biotechnology company pioneering tissue restorative biologics for chronic muscle ...